Veracyte

AI genomic diagnostics for cancer classification and treatment guidance

AI Healthcare & MedicalPaid

Veracyte is a genomic diagnostics company that uses AI and machine learning to classify ambiguous cancer cases and guide treatment decisions through genomic testing. Its flagship products include Afirma for thyroid cancer, Prosigna for breast cancer, and Decipher for prostate cancer — each combining genomic profiling with AI-trained classifiers to provide clinically actionable answers in situations where traditional pathology is indeterminate. Veracyte's tests help patients avoid unnecessary surgeries, receive more appropriate treatment intensity, and achieve better long-term outcomes. The company's AI models are trained on large datasets of patient outcomes to ensure predictions are clinically meaningful.

Key Features

• ✓Thyroid cancer classification
• ✓Breast cancer prognosis
• ✓Prostate cancer risk scoring
• ✓Indeterminate biopsy resolution
• ✓Surgery avoidance guidance